Long-Term Study of IGE025 in Moderate to Severe Bronchial Asthma.

Completed · Phase 3

Conditions studied: Asthma

In brief

This study will evaluate the safety and efficacy of omalizumab up to 48 weeks in adult patients with moderate to severe bronchial asthma. THIS STUDY IS NOT ENROLLING PATIENTS IN THE UNITED STATES

Key facts

Study ID

NCT00219323

Run by

Novartis

People needed

133

Starts

2003-11-01

Expected to finish

2006-03-01

Last updated by the study team

2011-10-25

Who can join

Age: 20 and older, up to 75. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Allergic asthma patients
• Inadequately controlled patients

You may not qualify if…

• - History of severe anaphylactoid or anaphylactic reactions
• Previous treatment with omalizumab
• History of cancer or cancer
• Other protocol-defined exclusion criteria may apply.

Where it is running

• This study is not being conducted in the United States — Tokyo, Japan

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.